DAN Stock Overview
Dancann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in various disease areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DanCann Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.0.0052 |
| 52 Week High | kr.0.04 |
| 52 Week Low | kr.0.0016 |
| Beta | 2.23 |
| 1 Month Change | -39.53% |
| 3 Month Change | 36.84% |
| 1 Year Change | -87.00% |
| 3 Year Change | -98.93% |
| 5 Year Change | n/a |
| Change since IPO | -99.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| DAN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | -0.7% |
| 1Y | -87.0% | -18.9% | 4.7% |
Return vs Industry: DAN underperformed the German Pharmaceuticals industry which returned -18.9% over the past year.
Return vs Market: DAN underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| DAN volatility | |
|---|---|
| DAN Average Weekly Movement | 45.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: DAN's share price has been volatile over the past 3 months.
Volatility Over Time: DAN's weekly volatility has increased from 32% to 45% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Jeppe Rasmussen | www.dancann.com |
Dancann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in various disease areas. The company produces and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. Dancann Pharma A/S was incorporated in 2018 and is based in Ansager, Denmark.
DanCann Pharma A/S Fundamentals Summary
| DAN fundamental statistics | |
|---|---|
| Market cap | €1.01m |
| Earnings (TTM) | -€8.22m |
| Revenue (TTM) | €916.19k |
1.1x
P/S Ratio-0.1x
P/E RatioIs DAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DAN income statement (TTM) | |
|---|---|
| Revenue | kr.6.83m |
| Cost of Revenue | kr.9.82m |
| Gross Profit | -kr.2.99m |
| Other Expenses | kr.58.34m |
| Earnings | -kr.61.33m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | -43.71% |
| Net Profit Margin | -897.54% |
| Debt/Equity Ratio | 0% |
How did DAN perform over the long term?
See historical performance and comparison